Stem cell factor inhibitor

ABSTRACT

Provided herein are methods, compositions, and uses relating to inhibitors of stem cell factor. For example, provided herein are antibodies targeting stem cell factor and methods for treating fibrotic and tissue remodeling diseases.

This application is a divisional of U.S. patent application Ser. No.13/937,852, filed Jul. 9, 2013, now U.S. Pat. No. 9,353,178, issued onMay 31, 2016, which is a divisional of U.S. patent application Ser. No.13/347,459, filed on Jan. 10, 2012, now U.S. Pat. No. 8,911,729, issuedon Dec. 16, 2014, which claims priority to U.S. Patent Application Ser.No. 61/431,246 filed on Jan. 10, 2011, each of which is incorporatedherein by reference in its entirety for all purposes.

STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT

This invention was made with government support under HL059178 awardedby the National Institutes of Health. The government has certain rightsin the invention.

FIELD OF INVENTION

Provided herein are methods, compositions, and uses relating toinhibitors of stem cell factor. For example, provided herein areantibodies targeting stem cell factor and methods for treating fibroticand tissue remodeling diseases.

BACKGROUND

Diseases involving tissue remodeling and fibrosis are a leading cause ofdeath worldwide. Nearly 45 percent of all natural deaths in the westernworld are attributable to some type of chronic fibroproliferativedisease and the associated health care costs are in the billions ofdollars. Tissue remodeling is the reorganization or renovation ofexisting tissues, which can either change the characteristics of atissue (e.g., blood vessel remodeling) or participate in establishingthe dynamic equilibrium of a tissue (e.g., bone remodeling). Fibrosis isthe formation or development of excess fibrous connective tissue in anorgan or tissue as a reparative or reactive process, as opposed toformation of fibrous tissue as a normal constituent of an organ ortissue. Fibrosis affects nearly all tissues and organ systems, andfibrotic tissue remodeling can influence cancer metastasis andaccelerate chronic graft rejection in transplant recipients. Diseases inwhich fibrosis is a major cause of morbidity and mortality include theinterstitial lung diseases, liver cirrhosis, kidney disease, heartdisease, and systemic sclerosis, among others.

Stem cell factor (SCF) and its receptor c-Kit have been implicated infibrotic and tissue remodeling diseases (El-Koraie, et al., Kidney Int.60: 167 (2001); Powell, et al., Am. J. Physiol. 289: G2 (2005); ElKossi, et al., Am. J. Kidney Dis. 41: 785 (2003); Powell, et al., Am. J.Physiol. 277: C183 (1999)). c-Kit is a type III receptor-tyrosine kinasethat is present in many cell types (Orr-Urtreger et al., Development109: 911 (1990)). It is also expressed in the early stages ofdifferentiation (Andre et al., Oncogene 4: 1047 (1989)) and certaintumors exhibit elevated expression of c-kit. SCF is a ligand specificfor the c-Kit receptor kinase. Binding causes dimerization of c-Kit andactivation of its kinase activity. SCF was first isolated from thesupernatant of murine fibroblasts. At the time, SCF was called mast cellgrowth factor (MGF) (Williams et al., Cell 63: 167 (1990)) orhematopoietic growth factor KL (Kit ligand) (Huang et al., Cell 63: 225(1990)). A homologue was subsequently isolated from rat liver cells anddesignated stem cell factor (SCF) (Zsebo et al., Cell 63: 195 (1990)).The corresponding human protein is designated variously as SCF, MGF, orSteel Factor (SF) (Cell 63: 203 (1990)).

Previous studies have suggested that an inhibitor of c-Kit receptortyrosine kinase can significantly inhibit aberrant tissue fibrosis (see,e.g., Aono, Am. J. Respir. Crit. Care Med. 171: 1279 (2005); Vuorinen,et al., Exp. Lung Res. 33: 357 (2007); Vittal, et al., J. Pharmacol.Exp. Ther. 321: 35 (2007); Distler, et al., Arthritis Rheum 56: 311(2007)). However, this inhibitor has several disadvantages. It needs tobe given systemically by oral administration, it has some toxicityassociated with its use, and the compound must be deliveredintracellularly for efficacy. Consequently, alternative therapies areneeded.

SUMMARY

Provided herein are methods, compositions, and uses relating toinhibitors of stem cell factor. For example, provided herein areantibodies targeting stem cell factor and methods for treating fibroticand tissue remodeling diseases as well as for research and diagnosticuses.

In some embodiments, the compositions, methods, and uses herein providetherapies relating to inhibiting stem cell factor (SCF). Someembodiments provide an isolated antibody that targets SCF. In someembodiments, inhibiting SCF affects the activity of c-Kit. Thecompositions, methods, and uses provided herein find use in treatingfibrotic diseases and maladies associated with tissue remodeling. Unlikesome other therapies that produce undesirable side effects due tointerfering with general intracellular signaling pathways, theembodiments provided herein eliminate or minimize such side effects bymodulating the activity of SCF. Consequently, toxicity is minimized.Moreover, targeting an extracellular ligand removes the need to delivera composition into a cell to interact with an intracellular target. Insome embodiments, the compositions are delivered into the airway, thusproviding an advantage over previous technologies that require oraladministration and, as such, resulting in systemic bioavailability.

Provided herein are embodiments of methods for treating a fibrotic ortissue remodeling disease comprising administering a therapeuticallyeffective amount of a stem cell factor inhibitor to a subject with or atrisk for a fibrotic or tissue remodeling disease. For example, in someembodiments, provided herein are methods comprising providing aninhibitor of stem cell factor and administering a therapeuticallyeffective amount of the inhibitor to a subject. In some embodiments theinhibitor is an isolated antibody (e.g., a monoclonal or polyclonalantibody) or an antigen-binding fragment thereof (e.g., Fab, Fab′,F(ab′)₂, and Fv fragments, etc.). In some embodiments the inhibitor is asmall interfering RNA. In more specific embodiments, the antibody is amonoclonal antibody or a polyclonal antibody. Some embodiments providethat the antibody or antigen-binding fragment thereof specifically bindsto stem cell factor. Some embodiments provide that the antibody orantigen-binding fragment thereof specifically binds to a peptidecomprising amino acid sequence SEQ ID NO: 1 or SEQ ID NO: 8.

In some embodiments of the methods provided herein, the subject has adisease. Accordingly, some embodiments provide that administering theinhibitor prevents or reduces the severity of at least one sign orsymptom of the disease. In some embodiments, the subject has an abnormalactivity of stem cell factor or the subject has abnormal collagenproduction. In some embodiments, the subject has a disease including,but not limited to, fibrosis or a remodeling disease. In additionalembodiments, the disease is a pulmonary disease. Some embodimentsprovide that a subject has a pulmonary disease including, but notlimited to, idiopathic pulmonary fibrosis, chronic obstructive pulmonarydisease, acute respiratory distress syndrome, cystic fibrosis,peribronchial fibrosis, hypersensitivity pneumonitis, or asthma. Inaddition, some embodiments provide that a subject has a diseaseincluding, but not limited to, sclerodoma, inflammation, livercirrhosis, renal fibrosis, parenchymal fibrosis, endomyocardialfibrosis, mediatinal fibrosis, nodular subepidermal fibrosis, fibroushistiocytoma, fibrothorax, hepatic fibrosis, fibromyalgia, gingivalfibrosis, or radiation-induced fibrosis.

While not limited in the mode of administration, in some embodiments ofthe method, the antibody is delivered into an airway of the subject,e.g., by intranasal administration.

In some embodiments, administering the inhibitor reduces the activity ofa receptor. Some embodiments provide that administering the inhibitorreduces an interaction of stem cell factor with a receptor. In morespecific embodiments, the receptor is a receptor tyrosine kinase, and inyet more specific embodiments, the receptor is c-Kit. Importantly, themethods are not limited in the location of the targeted receptor or theorigin of stem cell factor. For example, in some embodiments thereceptor is found on a hematopoietic progenitor cell, a melanocyte, agerm cell, an eosinophil, a lymphocyte, a fibroblast, a myofibroblast,or a mast cell. Additionally, in some embodiments, stem cell factororiginates from a bone marrow cell, a liver cell, an epithelial cell, asmooth muscle cell, or a fibroblast. In some embodiments, administeringthe inhibitor to a subject results in a direct inhibition of fibroblastactivation.

Some embodiments provide a composition comprising an isolated antibody(e.g., a monoclonal or a polyclonal antibody) or antigen-bindingfragment thereof that specifically binds to stem cell factor (e.g., aprotein or a peptide fragment thereof (e.g., an epitope)). For example,some embodiments provide a composition comprising an isolated antibodyor antigen-binding fragment thereof that specifically binds to a peptideof amino acid sequence SEQ ID NO: 1 or SEQ ID NO: 8. Additionalembodiments provide an antibody or antigen-binding fragment than bindsto the SCF isoform b precursor (e.g., a protein or peptide fragment ofthe sequence available at GenBank accession number NP_000890 (SEQ ID NO:4)), or a variant or modified form thereof, or to the SCF isoform aprecursor (e.g., a protein or peptide fragment of the sequence availableat GenBank accession number NP_003985 (SEQ ID NO: 6)), or a variant ormodified form thereof. Some embodiments provide an antibody orantigen-binding fragment that binds to a protein or peptide, or variantsor modified forms thereof, that is a translation product of the NCBIReference Gene Sequence for SCF (e.g., accession number NG_012098 (SEQID NO: 7)) or variants or fragments thereof. Some embodiments provide anantibody or antigen-binding fragment that binds to a peptide comprisingthe first 11 amino acids of the mature form of SCF (e.g., EGICRNRVTNN(SEQ ID NO: 8)).

Some embodiments provide an antibody or antigen-binding fragment thanbinds to the translation product (e.g., a protein or peptide), or avariant or modified form thereof, of a nucleic acid encoding SCF, or avariant or a modified form thereof. For example, embodiments provide anantibody or antigen-binding fragment than binds to the translationproduct (e.g., a protein or peptide), or a variant or modified formthereof, of the nucleic acids having sequences comprising a sequence asdefined by GenBank accession numbers NM_000899 (SEQ ID NO: 3), NM_003994(SEQ ID NO: 5), and NG_012098 (SEQ ID NO: 7), or fragments or variantsthereof (e.g., mutants, cDNAs, expression-optimized variants, operablylinked to a regulatory element (e.g., promoter, enhancer, polymerasebinding site, etc.), etc.). In some embodiments, the antibody orantigen-binding fragment binds to a protein or peptide, or a variant ormodified form thereof, that is the translation product of a nucleotidesequence that encodes the peptide sequence EGICRNRVTNN (SEQ ID NO: 8).The peptides and proteins (and fragments and variants thereof) and thenucleic acids (and fragments and variants thereof) that encode thepeptides and proteins (and fragments and variants thereof) are used insome embodiments to raise antibodies. Also contemplated are vectors,plasmids, expression constructs, cells, cell lines, hybridomas, andorganisms used to produce the antibodies as provided herein.

Some embodiments provide a monoclonal antibody and some embodimentsprovide a humanized antibody. In some embodiments, the composition isused for a medicament or is used for the manufacture of a medicament. Insome embodiments, the medicament is used to treat disease. Use of thecomposition as a medicament is not limited in the disease that can betreated. For example, in some embodiments, the disease is idiopathicpulmonary fibrosis, chronic obstructive pulmonary disease, acuterespiratory distress syndrome, cystic fibrosis, peribronchial fibrosis,hypersensitivity pneumonitis, asthma, sclerodoma, inflammation, livercirrhosis, renal fibrosis, parenchymal fibrosis, endomyocardialfibrosis, mediatinal fibrosis, nodular subepidermal fibrosis, fibroushistiocytoma, fibrothorax, hepatic fibrosis, fibromyalgia, gingivalfibrosis, or radiation-induced fibrosis. In some embodiments, thecomposition is used to study disease in vitro or in a model system(e.g., in vivo).

Embodiments provide herein a method of preparing an antibody (e.g., amonoclonal antibody) targeting stem cell factor comprising the steps ofproviding a peptide comprising or consisting of an immunogenic portionof SCF (e.g., as provided by SEQ ID NO: 1 or 8), immunizing a host withthe peptide, isolating an immune cell from the host, preparing ahybridoma using the immune cell, and isolating the antibody orantigen-binding fragment thereof. Some embodiments provide a method ofpreparing an antibody (e.g., a monoclonal antibody) targeting stem cellfactor, wherein the antibody or antigen-binding fragment thereofspecifically binds to stem cell factor (e.g., a protein or a peptidefragment thereof (e.g., an epitope)). For example, some embodimentsprovide a method of preparing an isolated antibody or antigen-bindingfragment thereof that specifically binds to a peptide of amino acidsequence SEQ ID NO: 1. Additional embodiments provide a method ofpreparing an antibody or antigen-binding fragment than binds to the SCFisoform b precursor (e.g., a protein or peptide fragment of the sequenceavailable at GenBank accession number NP_000890 (SEQ ID NO: 4)), or avariant or modified form thereof, or to the SCF isoform a precursor(e.g., a protein or peptide fragment of the sequence available atGenBank accession number NP_003985 (SEQ ID NO: 6)), or a variant ormodified form thereof. Some embodiments provide a method of preparing anantibody or antigen-binding fragment that binds to a protein or peptide,or variants or modified forms thereof, that is a translation product ofthe NCBI Reference Gene Sequence for SCF (e.g., accession numberNG_012098 (SEQ ID NO: 7)) or variants or fragments thereof. Someembodiments provide a method of preparing an antibody or antigen-bindingfragment that binds to a peptide comprising the first 11 amino acids ofthe mature form of SCF (e.g., EGICRNRVTNN (SEQ ID NO: 8)).

Some embodiments provide a method of preparing an antibody orantigen-binding fragment than binds to the translation product (e.g., aprotein or peptide), or a variant or modified form thereof, of a nucleicacid encoding SCF, or a variant or a modified form thereof. For example,embodiments provide a method of preparing an antibody or antigen-bindingfragment than binds to the translation product (e.g., a protein orpeptide), or a variant or modified form thereof, of the nucleic acidshaving sequences comprising a sequence as defined by GenBank accessionnumbers NM_000899 (SEQ ID NO: 3), NM_003994 (SEQ ID NO: 5), andNG_012098 (SEQ ID NO: 7), or fragments or variants thereof (e.g.,mutants, cDNAs, expression-optimized variants, operably linked to aregulatory element (e.g., promoter, enhancer, polymerase binding site,etc.), etc.). In some embodiments, the antibody or antigen-bindingfragment binds to a protein or peptide, or a variant or modified formthereof, that is the translation product of a nucleotide sequence thatencodes the peptide sequence EGICRNRVTNN (SEQ ID NO: 8). The peptides,proteins, and fragments and variants thereof; and nucleic acids, andfragments and variants thereof, that encode the peptides, proteins, andfragments and variants thereof, find use in some embodiments in a methodof preparing antibodies as provided by the technology provided. Alsocontemplated are methods of producing vectors, plasmids, expressionconstructs, cells, cell lines, hybridomas, and organisms that find usein producing the antibodies as provided herein.

Some embodiments provide a method comprising the steps of providing aninhibitor of stem cell factor and administering the inhibitor to a cellor tissue.

In addition, some embodiments provide a kit comprising a compositioncomprising an isolated antibody or antigen-binding fragment thereof thatspecifically binds to stem cell factor, a means for administering thecomposition to a subject, and/or instructions for use.

Additional embodiments will be apparent to persons skilled in therelevant art based on the teachings contained herein.

BRIEF DESCRIPTION OF THE DRAWINGS

These and other features, aspects, and advantages of the presenttechnology will become better understood with regard to the followingdrawings:

FIG. 1 shows a series of plots demonstrating that inhibiting SCF with anantibody reduces the expression of tissue remodeling mediators. FIG. 1Ashows a plot demonstrating that an anti-SCF antibody reduces the amountof hydroxyproline in bleomycin treated lung; FIG. 1B shows a plotdemonstrating that an anti-SCF antibody reduces the amount of IL-25mRNA; FIG. 1C shows a plot demonstrating that an anti-SCF antibodyreduces the amount of IL-13 mRNA; FIG. 1D shows a plot demonstratingthat an anti-SCF antibody reduces the amount of soluble SCF present inplasma. FIG. 1E shows a plot demonstrating that an anti-SCF antibodyreduces the amount of IL-25 receptor.

FIG. 2 shows a plot demonstrating that IL-4 stimulates c-kit expressionin human fibroblasts.

FIG. 3 shows an amino acid sequence and the corresponding nucleotidesequence of an immunogenic peptide used to produce antibodies specificfor SCF.

FIG. 4 shows a plot demonstrating that a monoclonal antibody specificfor SCF inhibits the activation of HMC-1 cells for MCP-1 production.

FIG. 5 shows a plot demonstrating that a lower amount of hydroxyprolineis detected in a mouse deficient in SCF production after bleomycininjury.

DETAILED DESCRIPTION

Provided herein are methods, compositions, and uses relating toinhibitors of stem cell factor. For example, provided herein areantibodies targeting stem cell factor, methods of producing antibodiestargeting stem cell factor, and methods for treating fibrotic and tissueremodeling diseases as well as for research and diagnostic uses. In someembodiments, the compositions, methods, and uses herein providetherapies relating to inhibiting stem cell factor (SCF). Someembodiments provide an isolated antibody that targets SCF. In someembodiments, inhibiting SCF affects the activity of c-Kit. Thecompositions, methods, and uses provided herein find use in treatingfibrotic diseases and maladies associated with tissue remodeling.

Definitions

To facilitate an understanding of embodiments of the present technology,a number of terms and phrases are defined below. Additional definitionsare set forth throughout the detailed description.

Throughout the specification and claims, the following terms take themeanings explicitly associated herein, unless the context clearlydictates otherwise. The phrase “in one embodiment” as used herein doesnot necessarily refer to the same embodiment, though it may.Furthermore, the phrase “in another embodiment” as used herein does notnecessarily refer to a different embodiment, although it may. Thus, asdescribed below, various embodiments of the invention may be readilycombined, without departing from the scope or spirit of the invention.

In addition, as used herein, the term “or” is an inclusive “or” operatorand is equivalent to the term “and/or” unless the context clearlydictates otherwise. The term “based on” is not exclusive and allows forbeing based on additional factors not described, unless the contextclearly dictates otherwise. In addition, throughout the specification,the meaning of “a”, “an”, and “the” include plural references. Themeaning of “in” includes “in” and “on.”

The terms “protein” and “polypeptide” refer to compounds comprisingamino acids joined via peptide bonds and are used interchangeably. A“protein” or “polypeptide” encoded by a gene is not limited to the aminoacid sequence encoded by the gene, but includes post-translationalmodifications of the protein.

Where the term “amino acid sequence” is recited herein to refer to anamino acid sequence of a protein molecule, “amino acid sequence” andlike terms, such as “polypeptide” or “protein” are not meant to limitthe amino acid sequence to the complete, native amino acid sequenceassociated with the recited protein molecule. Furthermore, an “aminoacid sequence” can be deduced from the nucleic acid sequence encodingthe protein.

The term “nascent” when used in reference to a protein refers to a newlysynthesized protein, which has not been subject to post-translationalmodifications, which includes but is not limited to glycosylation andpolypeptide shortening. The term “mature” when used in reference to aprotein refers to a protein which has been subject to post-translationalprocessing and/or which is in a cellular location (such as within amembrane or a multi-molecular complex) from which it can perform aparticular function which it could not if it were not in the location.

The term “portion” when used in reference to a protein (as in “a portionof a given protein”) refers to fragments of that protein. The fragmentsmay range in size from four amino acid residues to the entire aminosequence minus one amino acid (for example, the range in size includes4, 5, 6, 7, 8, 9, 10, or 11 . . . amino acids up to the entire aminoacid sequence minus one amino acid).

The term “homolog” or “homologous” when used in reference to apolypeptide refers to a high degree of sequence identity between twopolypeptides, or to a high degree of similarity between thethree-dimensional structure or to a high degree of similarity betweenthe active site and the mechanism of action. In a preferred embodiment,a homolog has a greater than 60% sequence identity, and more preferablygreater than 75% sequence identity, and still more preferably greaterthan 90% sequence identity, with a reference sequence.

The terms “variant” and “mutant” when used in reference to a polypeptiderefer to an amino acid sequence that differs by one or more amino acidsfrom another, usually related polypeptide. The variant may have“conservative” changes, wherein a substituted amino acid has similarstructural or chemical properties. One type of conservative amino acidsubstitutions refers to the interchangeability of residues havingsimilar side chains. For example, a group of amino acids havingaliphatic side chains is glycine, alanine, valine, leucine, andisoleucine; a group of amino acids having aliphatic-hydroxyl side chainsis serine and threonine; a group of amino acids having amide-containingside chains is asparagine and glutamine; a group of amino acids havingaromatic side chains is phenylalanine, tyrosine, and tryptophan; a groupof amino acids having basic side chains is lysine, arginine, andhistidine; and a group of amino acids having sulfur-containing sidechains is cysteine and methionine. Preferred conservative amino acidssubstitution groups are: valine-leucine-isoleucine,phenylalanine-tyrosine, lysine-arginine, alanine-valine, andasparagine-glutamine. More rarely, a variant may have “non-conservative”changes (e.g., replacement of a glycine with a tryptophan). Similarminor variations may also include amino acid deletions or insertions(i.e., additions), or both. Guidance in determining which and how manyamino acid residues may be substituted, inserted or deleted withoutabolishing biological activity may be found using computer programs wellknown in the art, for example, DNAStar software. Variants can be testedin functional assays. Preferred variants have less than 10%, andpreferably less than 5%, and still more preferably less than 2% changes(whether substitutions, deletions, and so on).

The term “domain” when used in reference to a polypeptide refers to asubsection of the polypeptide which possesses a unique structural and/orfunctional characteristic; typically, this characteristic is similaracross diverse polypeptides. The subsection typically comprisescontiguous amino acids, although it may also comprise amino acids whichact in concert or which are in close proximity due to folding or otherconfigurations. Examples of a protein domain include the transmembranedomains, and the glycosylation sites.

The term “gene” refers to a nucleic acid (e.g., DNA or RNA) sequencethat comprises coding sequences necessary for the production of an RNA,or a polypeptide or its precursor (e.g., proinsulin). A functionalpolypeptide can be encoded by a full length coding sequence or by anyportion of the coding sequence as long as the desired activity orfunctional properties (e.g., enzymatic activity, ligand binding, signaltransduction, etc.) of the polypeptide are retained. The term “portion”when used in reference to a gene refers to fragments of that gene. Thefragments may range in size from a few nucleotides to the entire genesequence minus one nucleotide. Thus, “a nucleotide comprising at least aportion of a gene” may comprise fragments of the gene or the entiregene.

The term “gene” also encompasses the coding regions of a structural geneand includes sequences located adjacent to the coding region on both the5′ and 3′ ends for a distance of about 1 kb on either end such that thegene corresponds to the length of the full-length mRNA. The sequenceswhich are located 5′ of the coding region and which are present on themRNA are referred to as 5′ non-translated sequences. The sequences whichare located 3′ or downstream of the coding region and which are presenton the mRNA are referred to as 3′ non-translated sequences. The term“gene” encompasses both cDNA and genomic forms of a gene. A genomic formor clone of a gene contains the coding region interrupted withnon-coding sequences termed “introns” or “intervening regions” or“intervening sequences.” Introns are segments of a gene which aretranscribed into nuclear RNA (hnRNA); introns may contain regulatoryelements such as enhancers. Introns are removed or “spliced out” fromthe nuclear or primary transcript; introns therefore are absent in themessenger RNA (mRNA) transcript. The mRNA functions during translationto specify the sequence or order of amino acids in a nascentpolypeptide.

In addition to containing introns, genomic forms of a gene may alsoinclude sequences located on both the 5′ and 3′ end of the sequenceswhich are present on the RNA transcript. These sequences are referred toas “flanking” sequences or regions (these flanking sequences are located5′ or 3′ to the non-translated sequences present on the mRNAtranscript). The 5′ flanking region may contain regulatory sequencessuch as promoters and enhancers which control or influence thetranscription of the gene. The 3′ flanking region may contain sequenceswhich direct the termination of transcription, posttranscriptionalcleavage and polyadenylation.

The terms “oligonucleotide” or “polynucleotide” or “nucleotide” or“nucleic acid” refer to a molecule comprised of two or moredeoxyribonucleotides or ribonucleotides, preferably more than three, andusually more than ten. The exact size will depend on many factors, whichin turn depends on the ultimate function or use of the oligonucleotide.The oligonucleotide may be generated in any manner, including chemicalsynthesis, DNA replication, reverse transcription, or a combinationthereof.

The terms “an oligonucleotide having a nucleotide sequence encoding agene” or “a nucleic acid sequence encoding” a specified polypeptiderefer to a nucleic acid sequence comprising the coding region of a geneor in other words the nucleic acid sequence which encodes a geneproduct. The coding region may be present in either a cDNA, genomic DNAor RNA form. When present in a DNA form, the oligonucleotide may besingle-stranded (i.e., the sense strand) or double-stranded. Suitablecontrol elements such as enhancers/promoters, splice junctions,polyadenylation signals, etc. may be placed in close proximity to thecoding region of the gene if needed to permit proper initiation oftranscription and/or correct processing of the primary RNA transcript.Alternatively, the coding region utilized in the expression vectors ofthe present invention may contain endogenous enhancers/promoters, splicejunctions, intervening sequences, polyadenylation signals, etc. or acombination of both endogenous and exogenous control elements.

The term “recombinant” when made in reference to a nucleic acid moleculerefers to a nucleic acid molecule which is comprised of segments ofnucleic acid joined together by means of molecular biologicaltechniques. The term “recombinant” when made in reference to a proteinor a polypeptide refers to a protein molecule which is expressed using arecombinant nucleic acid molecule.

The terms “complementary” and “complementarity” refer to polynucleotides(i.e., a sequence of nucleotides) related by the base-pairing rules. Forexample, for the sequence “5′-A-G-T-3′,” is complementary to thesequence “3′-T-C-A-S′.” Complementarity may be “partial,” in which onlysome of the nucleic acids' bases are matched according to the basepairing rules. Or, there may be “complete” or “total” complementaritybetween the nucleic acids. The degree of complementarity between nucleicacid strands has significant effects on the efficiency and strength ofhybridization between nucleic acid strands. This is of particularimportance in amplification reactions, as well as detection methodswhich depend upon binding between nucleic acids.

The term “wild-type” when made in reference to a gene refers to a genethat has the characteristics of a gene isolated from a naturallyoccurring source. The term “wild-type” when made in reference to a geneproduct refers to a gene product that has the characteristics of a geneproduct isolated from a naturally occurring source. The term“naturally-occurring” as applied to an object refers to the fact that anobject can be found in nature. For example, a polypeptide orpolynucleotide sequence that is present in an organism (includingviruses) that can be isolated from a source in nature and which has notbeen intentionally modified by man in the laboratory isnaturally-occurring. A wild-type gene is frequently that gene which ismost frequently observed in a population and is thus arbitrarilydesignated the “normal” or “wild-type” form of the gene. In contrast,the term “modified” or “mutant” when made in reference to a gene or to agene product refers, respectively, to a gene or to a gene product whichdisplays modifications in sequence and/or functional properties (i.e.,altered characteristics) when compared to the wild-type gene or geneproduct. It is noted that naturally-occurring mutants can be isolated;these are identified by the fact that they have altered characteristicswhen compared to the wild-type gene or gene product.

The term “allele” refers to different variations in a gene; thevariations include but are not limited to variants and mutants,polymorphic loci and single nucleotide polymorphic loci, frameshift andsplice mutations. An allele may occur naturally in a population, or itmight arise during the lifetime of any particular individual of thepopulation.

Thus, the terms “variant” and “mutant” when used in reference to anucleotide sequence refer to an nucleic acid sequence that differs byone or more nucleotides from another, usually related nucleotide acidsequence. A “variation” is a difference between two different nucleotidesequences; typically, one sequence is a reference sequence.

The term “antisense” refers to a deoxyribonucleotide sequence whosesequence of deoxyribonucleotide residues is in reverse 5′ to 3′orientation in relation to the sequence of deoxyribonucleotide residuesin a sense strand of a DNA duplex. A “sense strand” of a DNA duplexrefers to a strand in a DNA duplex which is transcribed by a cell in itsnatural state into a “sense mRNA.” Thus an “antisense” sequence is asequence having the same sequence as the non-coding strand in a DNAduplex. The term “antisense RNA” refers to a RNA transcript that iscomplementary to all or part of a target primary transcript or mRNA andthat blocks the expression of a target gene by interfering with theprocessing, transport and/or translation of its primary transcript ormRNA. The complementarity of an antisense RNA may be with any part ofthe specific gene transcript, i.e., at the 5′ non-coding sequence, 3′non-coding sequence, introns, or the coding sequence. In addition, asused herein, antisense RNA may contain regions of ribozyme sequencesthat increase the efficacy of antisense RNA to block gene expression.“Ribozyme” refers to a catalytic RNA and includes sequence-specificendoribonucleases. “Antisense inhibition” refers to the production ofantisense RNA transcripts capable of preventing the expression of thetarget protein.

The term “primer” refers to an oligonucleotide, whether occurringnaturally as in a purified restriction digest or produced synthetically,which is capable of acting as a point of initiation of synthesis whenplaced under conditions in which synthesis of a primer extension productwhich is complementary to a nucleic acid strand is induced, (e.g., inthe presence of nucleotides and an inducing agent such as DNA polymeraseand at a suitable temperature and pH). The primer is preferably singlestranded for maximum efficiency in amplification, but may alternativelybe double stranded. If double stranded, the primer is first treated toseparate its strands before being used to prepare extension products.Preferably, the primer is an oligodeoxyribonucleotide. The primer mustbe sufficiently long to prime the synthesis of extension products in thepresence of the inducing agent. The exact lengths of the primers willdepend on many factors, including temperature, source of primer and theuse of the method.

The term “probe” refers to an oligonucleotide (i.e., a sequence ofnucleotides), whether occurring naturally as in a purified restrictiondigest or produced synthetically, recombinantly or by PCR amplification,that is capable of hybridizing to another oligonucleotide of interest. Aprobe may be single-stranded or double-stranded. Probes are useful inthe detection, identification and isolation of particular genesequences. It is contemplated that any probe used in the presentinvention will be labeled with any “reporter molecule,” so that isdetectable in any detection system, including, but not limited to enzyme(e.g., ELISA, as well as enzyme-based histochemical assays),fluorescent, radioactive, and luminescent systems. It is not intendedthat the present invention be limited to any particular detection systemor label.

The term “isolated” when used in relation to a nucleic acid, as in “anisolated oligonucleotide” refers to a nucleic acid sequence that isidentified and separated from at least one contaminant nucleic acid withwhich it is ordinarily associated in its natural source. Isolatednucleic acid is present in a form or setting that is different from thatin which it is found in nature. In contrast, non-isolated nucleic acids,such as DNA and RNA, are found in the state they exist in nature.Examples of non-isolated nucleic acids include: a given DNA sequence(e.g., a gene) found on the host cell chromosome in proximity toneighboring genes; RNA sequences, such as a specific mRNA sequenceencoding a specific protein, found in the cell as a mixture withnumerous other mRNAs which encode a multitude of proteins. However,isolated nucleic acid encoding a particular protein includes, by way ofexample, such nucleic acid in cells ordinarily expressing the protein,where the nucleic acid is in a chromosomal location different from thatof natural cells, or is otherwise flanked by a different nucleic acidsequence than that found in nature. The isolated nucleic acid oroligonucleotide may be present in single-stranded or double-strandedform. When an isolated nucleic acid or oligonucleotide is to be utilizedto express a protein, the oligonucleotide will contain at a minimum thesense or coding strand (i.e., the oligonucleotide may single-stranded),but may contain both the sense and anti-sense strands (i.e., theoligonucleotide may be double-stranded).

The term “purified” refers to molecules, either nucleic or amino acidsequences, that are removed from their natural environment, isolated orseparated. An “isolated nucleic acid sequence” may therefore be apurified nucleic acid sequence. “Substantially purified” molecules areat least 60% free, preferably at least 75% free, and more preferably atleast 90% free from other components with which they are naturallyassociated. As used herein, the term “purified” or “to purify” alsorefer to the removal of contaminants from a sample. The removal ofcontaminating proteins results in an increase in the percent ofpolypeptide of interest in the sample. In another example, recombinantpolypeptides are expressed in plant, bacterial, yeast, or mammalian hostcells and the polypeptides are purified by the removal of host cellproteins; the percent of recombinant polypeptides is thereby increasedin the sample.

The term “composition comprising” a given polynucleotide sequence orpolypeptide refers broadly to any composition containing the givenpolynucleotide sequence or polypeptide. The composition may comprise anaqueous solution. Compositions comprising polynucleotide sequences orfragments thereof may be employed as hybridization probes. In someembodiments, polynucleotide sequences are employed in an aqueoussolution containing salts (e.g., NaCl), detergents (e.g., SDS), andother components (e.g., Denhardt's solution, dry milk, salmon sperm DNA,etc.).

The term “test compound” refers to any chemical entity, pharmaceutical,drug, and the like that can be used to treat or prevent a disease,illness, sickness, or disorder of bodily function, or otherwise alterthe physiological or cellular status of a sample. Test compoundscomprise both known and potential therapeutic compounds. A test compoundcan be determined to be therapeutic by screening using the screeningmethods of the present invention. A “known therapeutic compound” refersto a therapeutic compound that has been shown (e.g., through animaltrials or prior experience with administration to humans) to beeffective in such treatment or prevention.

As used herein, the term “antibody” is used in its broadest sense torefer to whole antibodies, monoclonal antibodies (including human,humanized, or chimeric antibodies), polyclonal antibodies, and antibodyfragments that can bind antigen (e.g., Fab′, F′ (ab)₂, Fv, single chainantibodies), comprising complementarity determining regions (CDRs) ofthe foregoing as long as they exhibit the desired biological activity.

As used herein, “antibody fragments” comprise a portion of an intactantibody, preferably the antigen binding or variable region of theintact antibody. Examples of antibody fragments include Fab, Fab′,F(ab′)₂, and Fv fragments; diabodies; linear antibodies (Zapata et al.,Protein Eng. 8(10): 1057-1062 (1995)); single-chain antibody molecules;and multispecific antibodies formed from antibody fragments.

An antibody that “specifically binds to” or is “specific for” aparticular polypeptide or an epitope on a particular polypeptide is onethat binds to that particular polypeptide or epitope on a particularpolypeptide without substantially binding to any other polypeptide orpolypeptide epitope.

As used herein, “active” or “activity” refers to native or naturallyoccurring biological and/or immunological activity.

As used herein the term, “in vitro” refers to an artificial environmentand to processes or reactions that occur within an artificialenvironment. In vitro environments may include, but are not limited to,test tubes and cell cultures. The term “in vivo” refers to the naturalenvironment (e.g., an animal or a cell) and to processes or reactionsthat occur within a natural environment.

As used herein, “inhibitor” refers to a molecule which eliminates,minimizes, or decreases the activity, e.g., the biological, enzymatic,chemical, or immunological activity, of a target.

As used herein the term “disease” refers to a deviation from thecondition regarded as normal or average for members of a species, andwhich is detrimental to an affected individual under conditions that arenot inimical to the majority of individuals of that species (e.g.,diarrhea, nausea, fever, pain, inflammation, etc.).

As used herein, the term “administration” refers to the act of giving adrug, prodrug, antibody, or other agent, or therapeutic treatment to aphysiological system (e.g., a subject or in vivo, in vitro, or ex vivocells, tissues, and organs). Exemplary routes of administration to thehuman body can be through the eyes (ophthalmic), mouth (oral), skin(transdermal), nose (nasal), lungs (inhalant), oral mucosa (buccal),ear, by injection (e.g., intravenously, subcutaneously, intratumorally,intraperitoneally, etc.) and the like. “Coadministration” refers toadministration of more than one chemical agent or therapeutic treatment(e.g., radiation therapy) to a physiological system (e.g., a subject orin vivo, in vitro, or ex vivo cells, tissues, and organs). As usedherein, administration “in combination with” one or more furthertherapeutic agents includes simultaneous (concurrent) and consecutiveadministration in any order. “Coadministration” of therapeutictreatments may be concurrent, or in any temporal order or physicalcombination.

As used herein, the term “treating” includes reducing or alleviating atleast one adverse effect or symptom of a disease or disorder throughintroducing in any way a therapeutic composition of the presenttechnology into or onto the body of a subject. “Treatment” refers toboth therapeutic treatment and prophylactic or preventative measures,wherein the object is to prevent or slow down (lessen) the targetedpathologic condition or disorder. Those in need of treatment includethose already with the disorder as well as those prone to have thedisorder or those in whom the disorder is to be prevented.

As used herein, “therapeutically effective dose” refers to an amount ofa therapeutic agent sufficient to bring about a beneficial or desiredclinical effect. Said dose can be administered in one or moreadministrations. However, the precise determination of what would beconsidered an effective dose may be based on factors individual to eachpatient, including, but not limited to, the patient's age, size, type orextent of disease, stage of the disease, route of administration, thetype or extent of supplemental therapy used, ongoing disease process,and type of treatment desired (e.g., aggressive vs. conventionaltreatment).

As used herein, the term “effective amount” refers to the amount of acomposition sufficient to effect beneficial or desired results. Aneffective amount can be administered in one or more administrations,applications, or dosages and is not intended to be limited to aparticular formulation or administration route.

As used herein, the term “pharmaceutical composition” refers to thecombination of an active agent with, as desired, a carrier, inert oractive, making the composition especially suitable for diagnostic ortherapeutic use in vitro, in vivo, or ex vivo.

As used herein, the terms “pharmaceutically acceptable” or“pharmacologically acceptable” refer to compositions that do notsubstantially produce adverse reactions, e.g., toxic, allergic, orimmunological reactions, when administered to a subject.

As used herein, “carriers” include pharmaceutically acceptable carriers,excipients, or stabilizers which are nontoxic to the cell or mammalbeing exposed thereto at the dosages and concentrations employed. Oftenthe physiologically acceptable carrier is an aqueous pH-bufferedsolution. Examples of physiologically acceptable carriers includebuffers such as phosphate, citrate, and other organic acids;antioxidants including ascorbic acid; low molecular weight (less thanabout 10 residues) polypeptides; proteins, such as serum albumin,gelatin, or immunoglobulins; hydrophilic polymers such aspolyvinylpyrrolidone; amino acids such as glycine, glutamine,asparagine, arginine, or lysine; monosaccharides, disaccharides, andother carbohydrates including glucose, mannose, or dextrins; chelatingagents such as EDTA; sugar alcohols such as mannitol or sorbitol;salt-forming counterions such as sodium; and/or nonionic surfactants.

As used herein, the terms “patient” or “subject” refer to organisms tobe treated by the compositions of the present technology or to besubject to various tests provided by the technology. The term “subject”includes animals, preferably mammals, including humans. In a preferredembodiment, the subject is a primate. In an even more preferredembodiment, the subject is a human.

As used herein, the term “sample” is used in its broadest sense. In onesense it can refer to animal cells or tissues. In another sense, it ismeant to include a specimen or culture obtained from any source, such asbiological and environmental samples. Biological samples may be obtainedfrom plants or animals (including humans) and encompass fluids, solids,tissues, and gases. Environmental samples include environmental materialsuch as surface matter, soil, water, and industrial samples. Theseexamples are not to be construed as limiting the sample types applicableto the present technology.

Embodiments of the Technology

Although the disclosure herein refers to certain illustratedembodiments, it is to be understood that these embodiments are presentedby way of example and not by way of limitation.

1. Inhibitors of SCF

Stem cell factor (SCF) is a ligand that is specific for the c-Kitreceptor kinase. Binding of SCF to c-Kit causes dimerization of c-Kitand activation of its kinase activity, which is important forhemopoiesis, melanogenesis, and fertility. Through c-Kit, SCF acts topromote cell survival, proliferation, differentiation, adhesion, andfunctional activation. Aberrant activation of c-Kit can result indisease, including fibrosis and tissue remodeling defects. Inparticular, there are multiple pulmonary diseases with known remodelingdefects as well as other chronic tissue remodeling diseases affectingother organs and tissues. Specific examples of diseases involvingfibrosis or tissue remodeling defects are idiopathic pulmonary fibrosis,chronic obstructive pulmonary disease, acute respiratory distresssyndrome, cystic fibrosis, peribronchial fibrosis, hypersensitivitypneumonitis, asthma, sclerodoma, inflammation, liver cirrhosis, renalfibrosis, parenchymal fibrosis, endomyocardial fibrosis, mediatinalfibrosis, nodular subepidermal fibrosis, fibrous histiocytoma,fibrothorax, hepatic fibrosis, fibromyalgia, gingival fibrosis, andradiation-induced fibrosis.

Accordingly, interfering with the interaction between SCF and c-Kit canbe used to treat or study diseases involving aberrant activation ofc-Kit that causes fibrosis and tissue remodeling defects. The c-Kitreceptor is found on hematopoietic progenitor cells, melanocytes, germcells, eosinophils, lymphocytes, and mast cells. Thus, preventing SCFinteraction with c-Kit can alter the activation of severaldisease-associated cell populations that have been implicated infibrosis and tissue remodeling disease phenotypes.

Additionally, SCF induces key mediators in the fibrotic response, IL-25and IL-13. Data suggest that IL-25 can drive IL-13 expression in aT-cell and antigen-independent manner. Therefore, these processes canprogress without an antigen-specific response and consequentlychronically perpetuate remodeling and fibrotic disease. It iscontemplated that a complex cascade is established in which SCF inducesIL-25, which in turn induces production of IL-13, myofibroblastdifferentiation, and collagen production. IL-4 has also been identifiedas a fibrosis-associated cytokine.

2. Antibodies

In some embodiments, inhibiting the ability of SCF to interact withc-Kit is accomplished by means of an antibody that recognizes SCF. Theantibody can be a monoclonal antibody or a polyclonal antibody, and maybe, for example, a human, humanized, or chimeric antibody. Monoclonalantibodies against target antigens are produced by a variety oftechniques including conventional monoclonal antibody methodologies suchas the somatic cell hybridization techniques of Köhler and Milstein(Nature, 256:495 (1975)). Although in some embodiments, somatic cellhybridization procedures are preferred, other techniques for producingmonoclonal antibodies are contemplated as well (e.g., viral or oncogenictransformation of B lymphocytes).

It is contemplated that antibodies against SCF find use in theexperimental, diagnostic, and therapeutic methods described herein. Incertain embodiments, the antibodies provided herein are used to detectthe expression of SCF in biological samples. For example, a samplecomprising a tissue biopsy can be sectioned and protein detected using,for example, immunofluorescence or immunohistochemistry. Alternatively,individual cells from a sample can be isolated, and protein expressiondetected on fixed or live cells by FACS analysis. Furthermore, theantibodies can be used on protein arrays to detect expression of SCF. Inother embodiments, the antibodies provided herein are used to decreasethe activity of cells expressing c-Kit by inhibiting SCF either in an invitro cell-based assay or in an in vivo animal model. In someembodiments, antibodies are used to treat a human patient byadministering a therapeutically effective amount of an antibody againstSCF.

For the production of antibodies, various host animals can be immunizedby injection with the peptide corresponding to the desired epitope(e.g., a fragment of SCF, e.g., a fragment comprising the sequenceprovided by SEQ ID NO: 1 or 8 or immunogenic portions thereof)including, but not limited to, rabbits, mice, rats, sheep, goats, etc.Antibodies to SCF can be raised by immunizing (e.g., by injection) withan antigen comprising a peptide, a portion, or the full protein of theSCF isoform b precursor (e.g., a protein or peptide fragment of thesequence available at GenBank accession number NP_000890 (SEQ ID NO:4)), or a variant or modified version thereof, or a peptide, a portion,or the full protein of the SCF isoform a precursor (e.g., a protein orpeptide fragment of the sequence available at GenBank accession numberNP_003985 (SEQ ID NO: 6)), or a variant or modified version thereof.Antibodies can also be raised by immunization with a translation productof the NCBI Reference Gene Sequence for SCF (e.g., accession numberNG_012098 (SEQ ID NO: 7)) or variants or fragments thereof.

In some embodiments, the peptide is conjugated to an immunogenic carrier(e.g., diphtheria toxoid, bovine serum albumin (BSA), or keyhole limpethemocyanin (KLH)). Various adjuvants are used to increase theimmunological response, depending on the host species, including, butnot limited to, Freund's (complete and incomplete), mineral gels such asaluminum hydroxide, surface active substances such as lysolecithin,pluronic polyols, polyanions, peptides, oil emulsions, keyhole limpethemocyanins, dinitrophenol, and potentially useful human adjuvants suchas BCG (Bacille Calmette-Guerin) and Corynebacterium parvum.

Polyclonal antibodies can be prepared by any known method. Polyclonalantibodies can be raised by immunizing an animal (e.g., a rabbit, rat,mouse, donkey, etc) by multiple subcutaneous or intraperitonealinjections of the relevant antigen (a purified peptide fragment,full-length recombinant protein, fusion protein, etc.) optionallyconjugated to KLH, serum albumin, etc., diluted in sterile saline, andcombined with an adjuvant to form a stable emulsion. The polyclonalantibody is then recovered from blood, ascites, and the like, of ananimal so immunized. Collected blood is clotted, and the serum decanted,clarified by centrifugation, and assayed for antibody titer. Thepolyclonal antibodies can be purified from serum or ascites according tostandard methods in the art including affinity chromatography,ion-exchange chromatography, gel electrophoresis, dialysis, etc.

For preparation of monoclonal antibodies, any technique that providesfor the production of antibody molecules by continuous cell lines inculture may be used (see e.g., Harlow and Lane, Antibodies: A LaboratoryManual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.).These include, but are not limited to, the hybridoma techniqueoriginally developed by Köhler and Milstein and the trioma technique,the human B-cell hybridoma technique (See, e.g., Kozbor et al., Immunol.Today, 4:72 (1983)), and the EBV-hybridoma technique to produce humanmonoclonal antibodies (Cole et al., in Monoclonal Antibodies and CancerTherapy, Alan R. Liss, Inc., pp. 77-96 (1985)).

In some embodiments provided herein, the antibodies are prepared from ahybridoma. Using the hybridoma method, a mouse, hamster, or otherappropriate host animal, is immunized as described above to elicit theproduction by lymphocytes of antibodies that will specifically bind toan immunizing antigen. Alternatively, lymphocytes can be immunized invitro. Following immunization, the lymphocytes are isolated and fusedwith a suitable myeloma cell line using, for example, polyethyleneglycol, to form hybridoma cells that can then be selected away fromunfused lymphocytes and myeloma cells. Hybridomas that producemonoclonal antibodies directed specifically against a chosen antigen asdetermined by immunoprecipitation, immunoblotting, or by an in vitrobinding assay such as radioimmunoassay (RIA) or enzyme-linkedimmunosorbent assay (ELISA) can then be propagated in vitro (e.g., inculture) using standard methods (Goding, Monoclonal Antibodies:Principles and Practice, Academic Press, 1986) or in vivo as ascitestumors in an animal. The monoclonal antibodies can then be purified fromthe culture medium or ascites fluid as described for polyclonalantibodies above.

The preferred animal system for preparing hybridomas is the murinesystem. Hybridoma production in the mouse is a well-establishedprocedure. Immunization protocols and techniques for isolation ofimmunized splenocytes for fusion are known in the art. Fusion partners(e.g., murine myeloma cells) and fusion procedures are also known.Embodiments of the technology herein provide antibodies (e.g.,monoclonal antibodies) produced from a hybridoma prepared by immunizingmice with a peptide that is a portion or fragment of the SCF protein.For example, some embodiments provide an antibody or antigen-bindingfragment than binds to SCF by immunizing with, e.g., a protein orpeptide fragment of the sequence available at GenBank accession numberNP_000890 (SEQ ID NO: 4)), or a variant or modified version thereof, orby immunizing with, e.g., a protein or peptide fragment of the sequenceavailable at GenBank accession number NP_003985 (SEQ ID NO: 6)), or avariant or modified version thereof. Some embodiments provide anantibody or antigen-binding fragment that binds to a protein or peptide,or variants or modified versions thereof, that is a translation productof the NCBI Reference Gene Sequence for SCF (e.g., accession numberNG_012098 (SEQ ID NO: 7)) or variants or fragments thereof.

For example, embodiments of the technology herein provide monoclonalantibodies produced from a hybridoma prepared by immunizing mice with apeptide of amino acid sequence SEQ ID NO: 1 or 8. Also contemplated aremethods and compositions related to antibodies prepared using a variantof SEQ ID NO: 1 or 8 comprising one or more substitutions, deletions,insertions, or other changes, as long as said variant produces anantibody specific for SCF. Producing polypeptides of SEQ ID NO: 1 or 8and similar sequences thereto can be accomplished according to varioustechniques well known in the art. For example, a polypeptide of SEQ IDNO: 1 or 8 or a variant thereof can be produced using a bacterialexpression system and a nucleic acid encoding a polypeptide of SEQ IDNO: 1 or 8 or a variant thereof. As an example, a polypeptide accordingto SEQ ID NO: 1 can be produced using the nucleotide sequence accordingto SEQ ID NO: 2.

Moreover, human monoclonal antibodies directed against human proteinscan be generated using transgenic mice carrying the complete humanimmune system rather than the mouse system. Splenocytes from thetransgenic mice are immunized with the antigen of interest, which areused to produce hybridomas that secrete human monoclonal antibodies withspecific affinities for epitopes from a human protein.

Monoclonal antibodies can also be generated by other methods known tothose skilled in the art of recombinant DNA technology. For instance,combinatorial antibody display has can be utilized to produce monoclonalantibodies (see, e.g., Sastry et al., Proc. Nat. Acad. Sci. USA, 86:5728 (1989); Huse et al., Science, 246: 1275 (1989); Orlandi et al.,Proc. Nat. Acad. Sci. USA, 86:3833 (1989)). After immunizing an animalwith an immunogen as described above, the antibody repertoire of theresulting B-cell pool is cloned. Methods are generally known forobtaining the DNA sequence of the variable regions of a diversepopulation of immunoglobulin molecules by using a mixture of oligomerprimers and PCR. For instance, mixed oligonucleotide primerscorresponding to the 5′ leader (signal peptide) sequences and/orframework 1 (FR1) sequences, as well as primers to a conserved 3′ regioncan be used to amplify and isolate the heavy and light chain variableregions from a number of murine antibodies (see. e.g., Larrick et al.,Biotechniques, 11: 152 (1991)). A similar strategy can also been used toamplify human heavy and light chain variable regions from humanantibodies (see, e.g., Larrick et al., Methods: Companion to Methods inEnzymology, 2: 106 (1991)).

Alternatively, monoclonal antibodies can also be made using recombinantDNA methods as described in U.S. Pat. No. 4,816,567. The polynucleotidesencoding a monoclonal antibody are isolated (e.g., from mature B-cellsor hybridoma cells), by, e.g., RT-PCR using oligonucleotide primers thatspecifically amplify the genes encoding the heavy and light chains ofthe antibody, and their sequences are determined using conventionalprocedures. The isolated polynucleotides encoding the heavy and lightchains are then cloned into suitable expression vectors, which, whentransfected into host cells such as E. coli cells, simian COS cells,Chinese hamster ovary (CHO) cells, or myeloma cells that do nototherwise produce immunoglobulin protein, cause monoclonal antibodies tobe generated by the host cells. Also, recombinant monoclonal antibodiesor fragments thereof of the desired species can be isolated from phagedisplay libraries as described (McCafferty et al., 1990, Nature,348:552-554; Clackson et al., 1991, Nature, 352:624-628; and Marks etal., 1991, J. Mol. Biol., 222:581-597).

The polynucleotide encoding a monoclonal antibody can further bemodified in a number of different manners using recombinant DNAtechnology to generate alternative antibodies. In one embodiment, theconstant domains of the light and heavy chains of, for example, a mousemonoclonal antibody can be substituted 1) for those regions of, forexample, a human antibody to generate a chimeric antibody or 2) for anon-immunoglobulin polypeptide to generate a fusion antibody. In otherembodiments, the constant regions are truncated or removed to generatethe desired antibody fragment of a monoclonal antibody. Furthermore,site-directed or high-density mutagenesis of the variable region can beused to optimize specificity, affinity, etc. of a monoclonal antibody.

For example, also contemplated are chimeric mouse-human monoclonalantibodies, which can be produced by recombinant DNA techniques known inthe art. For example, a gene encoding the constant region of a murine(or other species) monoclonal antibody molecule is digested withrestriction enzymes to remove the region encoding the murine constantregion, and the equivalent portion of a gene encoding a human constantregion is substituted (see, e.g., Robinson et al., PCT/US86/02269;European Patent Application 184,187; European Patent Application171,496; European Patent Application 173,494; WO 86/01533; U.S. Pat. No.4,816,567; European Patent Application 125,023 (each of which is hereinincorporated by reference in its entirety); Better et al., Science,240:1041-1043 (1988); Liu et al., Proc. Nat. Acad. Sci. USA,84:3439-3443 (1987); Liu et al., J. Immunol., 139:3521-3526 (1987); Sunet al., Proc. Nat. Acad. Sci. USA, 84:214-218 (1987); Nishimura et al.,Canc. Res., 47:999-1005 (1987); Wood et al., Nature, 314:446-449 (1985);and Shaw et al., J. Natl. Cancer Inst., 80:1553-1559 (1988)).

The chimeric antibody can be further humanized by replacing sequences ofthe variable region that are not directly involved in antigen bindingwith equivalent sequences from human variable regions. General reviewsof humanized chimeric antibodies are provided by S. L. Morrison,Science, 229:1202-1207 (1985) and by Oi et al., Bio Techniques, 4:214(1986). Those methods include isolating, manipulating, and expressingthe nucleic acid sequences that encode all or part of immunoglobulinvariable regions from at least one of a heavy or light chain. Sources ofsuch nucleic acid are well known to those skilled in the art. Therecombinant DNA encoding the chimeric antibody, or fragment thereof, canthen be cloned into an appropriate expression vector.

Suitable humanized antibodies can alternatively be produced by CDRsubstitution (see, e.g., U.S. Pat. No. 5,225,539; Jones et al., Nature,321:552-525 (1986); Verhoeyan et al., Science, 239:1534 (1988); andBeidler et al., J. Immunol., 141:4053 (1988)). All of the CDRs of aparticular human antibody may be replaced with at least a portion of anon-human CDR or only some of the CDRs may be replaced with non-humanCDRs. It is only necessary to replace the number of CDRs important forbinding of the humanized antibody to the Fc receptor.

An antibody can be humanized by any method that is capable of replacingat least a portion of a CDR of a human antibody with a CDR derived froma non-human antibody. The human CDRs may be replaced with non-human CDRsusing oligonucleotide site-directed mutagenesis.

Also contemplated are chimeric and humanized antibodies in whichspecific amino acids have been substituted, deleted, or added. Inparticular, preferred humanized antibodies have amino acid substitutionsin the framework region, such as to improve binding to the antigen. Forexample, in a humanized antibody having mouse CDRs, amino acids locatedin the human framework region can be replaced with the amino acidslocated at the corresponding positions in the mouse antibody. Suchsubstitutions are known to improve binding of humanized antibodies tothe antigen in some instances.

In certain embodiments provided herein, it is desirable to use anantibody fragment. Various techniques are known for the production ofantibody fragments. Traditionally, these fragments are derived viaproteolytic digestion of intact antibodies (for example Morimoto et al.,1993, Journal of Biochemical and Biophysical Methods 24:107-117 andBrennan et al., 1985, Science, 229:81). For example, papain digestion ofantibodies produces two identical antigen-binding fragments, called Fabfragments, each with a single antigen-binding site, and a residual Fcfragment. Pepsin treatment yields an F(ab′)₂ fragment that has twoantigen-combining sites and is still capable of cross-linking antigen.

However, these fragments are now typically produced directly byrecombinant host cells as described above. Thus Fab, Fv, and scFvantibody fragments can all be expressed in and secreted from E. coli orother host cells, thus allowing the production of large amounts of thesefragments. Alternatively, such antibody fragments can be isolated fromthe antibody phage libraries discussed above. The antibody fragment canalso be linear antibodies as described in U.S. Pat. No. 5,641,870, forexample, and can be monospecific or bispecific. Other techniques for theproduction of antibody fragments will be apparent to the skilledpractitioner.

Fv is the minimum antibody fragment which contains a completeantigen-recognition and antigen-binding site. This region consists of adimer of one heavy-chain and one light-chain variable domain in tight,non-covalent association. It is in this configuration that the threeCDRs of each variable domain interact to define an antigen-binding siteon the surface of the V_(H)-V_(L) dimer. Collectively, the six CDRsconfer antigen-binding specificity to the antibody. However, even asingle variable domain (or half of an Fv comprising only three CDRsspecific for an antigen) has the ability to recognize and bind antigen,although at a lower affinity than the entire binding site.

The Fab fragment also contains the constant domain of the light chainand the first constant domain (CH1) of the heavy chain. Fab fragmentsdiffer from Fab′ fragments by the addition of a few residues at thecarboxy terminus of the heavy chain CH1 domain including one or morecysteines from the antibody hinge region. F(ab′)₂ antibody fragmentsoriginally were produced as pairs of Fab′ fragments which have hingecysteines between them. Other chemical couplings of antibody fragmentsare also known to the skilled artisan.

The technology herein provided also contemplates modifying an antibodyto increase its serum half-life. This can be achieved, for example, byincorporating a salvage receptor binding epitope into the antibodyfragment by mutation of the appropriate region in the antibody fragmentor by incorporating the epitope into a peptide tag that is then fused tothe antibody fragment at either end or in the middle (e.g., by DNA orpeptide synthesis).

The technology embraces variants and equivalents which are substantiallyhomologous to the chimeric, humanized, and human antibodies, or antibodyfragments thereof, provided herein. These can contain, for example,conservative substitution mutations, i.e. the substitution of one ormore amino acids by similar amino acids. For example, conservativesubstitution refers to the substitution of an amino acid with anotherwithin the same general class such as, for example, one acidic aminoacid with another acidic amino acid, one basic amino acid with anotherbasic amino acid, or one neutral amino acid by another neutral aminoacid. What is intended by a conservative amino acid substitution is wellknown in the art.

An additional embodiment utilizes the techniques known in the art forthe construction of Fab expression libraries (Huse et al., Science,246:1275-1281 (1989)) to allow rapid and easy identification ofmonoclonal Fab fragments with the desired specificity.

Also, this technology encompasses bispecific antibodies thatspecifically recognize SCF. Bispecific antibodies are antibodies thatare capable of specifically recognizing and binding at least twodifferent epitopes. Bispecific antibodies can be intact antibodies orantibody fragments. Techniques for making bispecific antibodies arecommon in the art (Millstein et al., 1983, Nature 305:537-539; Brennanet al., 1985, Science 229:81; Suresh et al, 1986, Methods in Enzymol.121:120; Traunecker et al., 1991, EMBO J. 10:3655-3659; Shalaby et al.,1992, J. Exp. Med. 175:217-225; Kostelny et al., 1992, J. Immunol.148:1547-1553; Gruber et al., 1994, J. Immunol. 152:5368; and U.S. Pat.No. 5,731,168).

Techniques described for the production of single chain antibodies (U.S.Pat. No. 4,946,778; herein incorporated by reference) can be adapted toproduce specific single chain antibodies as desired. Single-chain Fvantibody fragments comprise the V_(H) and V_(L) domains of an antibody,wherein these domains are present in a single polypeptide chain.Preferably, the Fv polypeptide further comprises a polypeptide linkerbetween the V_(H) and V_(L) domains that enables the single-chain Fvantibody fragments to form the desired structure for antigen binding.For a review of single-chain Fv antibody fragments, see Pluckthun in ThePharmacology of Monoclonal Antibodies, vol. 113, Rosenburg and Mooreeds., Springer-Verlag, New York, pp. 269-315 (1994).

3. Other SCF Inhibitors

It is also contemplated that inhibiting SCF can be accomplished by avariety of other types of inhibitors. For example, in some embodiments asmall interfering RNA (siRNA) can be designed to target and degrade SCFmRNA. siRNAs are double-stranded RNA molecules of 20-25 nucleotides inlength. While not limited in their features, typically an siRNA is 21nucleotides long and has 2-nt 3′ overhangs on both ends. Each strand hasa 5′ phosphate group and a 3′ hydroxyl group. In vivo, this structure isthe result of processing by dicer, an enzyme that converts either longdsRNAs or small hairpin RNAs into siRNAs. However, siRNAs can also besynthesized and exogenously introduced into cells to bring about thespecific knockdown of a gene of interest. Essentially any gene of whichthe sequence is known can be targeted based on sequence complementaritywith an appropriately tailored siRNA. For example, those of ordinaryskill in the art can synthesize an siRNA (see, e.g., Elbashir, et al.,Nature 411: 494 (2001); Elbashir, et al. Genes Dev 15:188 (2001); TuschlT, et al., Genes Dev 13:3191 (1999)).

In some embodiments, RNAi is utilized to inhibit SCF. RNAi represents anevolutionarily conserved cellular defense for controlling the expressionof foreign genes in most eukaryotes, including humans. RNAi is typicallytriggered by double-stranded RNA (dsRNA) and causes sequence-specificdegradation of single-stranded target RNAs (e.g., an mRNA). Themediators of mRNA degradation are small interfering RNAs (siRNAs), whichare normally produced from long dsRNA by enzymatic cleavage in the cell.siRNAs are generally approximately twenty-one nucleotides in length(e.g. 21-23 nucleotides in length) and have a base-paired structurecharacterized by two nucleotide 3′ overhangs. Following the introductionof a small RNA, or RNAi, into the cell, it is believed the sequence isdelivered to an enzyme complex called RISC (RNA-induced silencingcomplex). RISC recognizes the target and cleaves it with anendonuclease. It is noted that if larger RNA sequences are delivered toa cell, an RNase III enzyme (e.g., Dicer) converts the longer dsRNA into21-23 nt double-stranded siRNA fragments. In some embodiments, RNAioligonucleotides are designed to target the junction region of fusionproteins. Chemically synthesized siRNAs have become powerful reagentsfor genome-wide analysis of mammalian gene function in cultured somaticcells. Beyond their value for validation of gene function, siRNAs alsohold great potential as gene-specific therapeutic agents (see, e.g.,Tuschl and Borkhardt, Molecular Intervent. 2002; 2(3): 158-67, hereinincorporated by reference).

The transfection of siRNAs into animal cells results in the potent,long-lasting post-transcriptional silencing of specific genes (Caplen etal, Proc Natl Acad Sci U.S.A. 2001; 98: 9742-47; Elbashir et al.,Nature. 2001; 411:4 94-98; Elbashir et al., Genes Dev. 2001; 15:188-200; and Elbashir et al., EMBO J. 2001; 20: 6877-88, all of whichare herein incorporated by reference). Methods and compositions forperforming RNAi with siRNAs are described, for example, in U.S. Pat. No.6,506,559, herein incorporated by reference.

siRNAs are extraordinarily effective at lowering the amounts of targetedRNA and their protein products, frequently to undetectable levels. Thesilencing effect can last several months, and is extraordinarilyspecific—a one-nucleotide mismatch between the target RNA and thecentral region of the siRNA is frequently sufficient to preventsilencing (Brummelkamp et al, Science 2002; 296: 550-53; and Holen etal, Nucleic Acids Res. 2002; 30: 1757-66, both of which are hereinincorporated by reference).

An important factor in the design of siRNAs is the presence ofaccessible sites for siRNA binding. Bahoia et al., (J. Biol. Chem.,2003; 278: 15991-97; herein incorporated by reference) describe the useof a type of DNA array called a scanning array to find accessible sitesin mRNAs for designing effective siRNAs. These arrays compriseoligonucleotides ranging in size from monomers to a certain maximum,usually Co-mers, synthesized using a physical barrier (mask) by stepwiseaddition of each base in the sequence. Thus the arrays represent a fulloligonucleotide complement of a region of the target gene. Hybridizationof the target mRNA to these arrays provides an exhaustive accessibilityprofile of this region of the target mRNA. Such data are useful in thedesign of antisense oligonucleotides (ranging from 7 mers to 25 mers),where it is important to achieve a compromise between oligonucleotidelength and binding affinity, e.g., to retain efficacy and targetspecificity (Sohail et al, Nucleic Acids Res., 2001; 29(10): 2041-45).Additional methods and concerns for selecting siRNAs are described, forexample, in WO 05054270, WO005038054A1, WO003070966A2, J Mol Biol. 2005May 13; 348(4):883-93, J Mol Biol. 2005 May 13; 348(4):871-81, andNucleic Acids Res. 2003 Aug. 1; 31(15):4417-24, each of which is hereinincorporated by reference in its entirety. In addition, software (e.g.,the MWG online siMAX siRNA design tool) is commercially or publiclyavailable for use in the selection and design of siRNAs and RNAireagents.

In some embodiments, the present invention utilizes siRNA includingblunt ends (See e.g., US20080200420, herein incorporated by reference inits entirety), overhangs (See e.g., US20080269147A1, herein incorporatedby reference in its entirety), locked nucleic acids (See e.g.,WO2008/006369, WO2008/043753, and WO2008/051306, each of which is hereinincorporated by reference in its entirety). In some embodiments, siRNAsare delivered via gene expression or using bacteria (See e.g., Xiang etal., Nature 24: 6 (2006) and WO06066048, each of which is hereinincorporated by reference in its entirety).

In other embodiments, shRNA techniques (See e.g., 20080025958, hereinincorporated by reference in its entirety) are utilized. A small hairpinRNA or short hairpin RNA (shRNA) is a sequence of RNA that makes a tighthairpin turn that can be used to silence gene expression via RNAinterference. shRNA uses a vector introduced into cells and utilizes theU6 promoter to ensure that the shRNA is always expressed. This vector isusually passed on to daughter cells, allowing the gene silencing to beinherited. The shRNA hairpin structure is cleaved by the cellularmachinery into siRNA, which is then bound to the RNA-induced silencingcomplex (RISC). This complex binds to and cleaves mRNAs which match thesiRNA that is bound to it. shRNA is transcribed by RNA polymerase III.

The present invention also includes pharmaceutical compositions andformulations that include the RNAi compounds of the present invention asdescribed below.

SCF exists in both transmembrane and soluble forms. Upon cleavage of theSCF soluble domain from the transmembrane form, SCF is released from thecell surface to function as the ligand of c-Kit. Thus, it iscontemplated that SCF activity can be altered by inhibiting the releaseof soluble SCF from the membrane-bound form, for example, by inhibitingor otherwise reducing the activity of a protease that cleaves thesoluble domain from the membrane-bound form.

In addition, it is contemplated that SCF can be inhibited by chemicals(e.g., a small molecule, e.g., a pharmacological agent) or otherbiological agents that bind or modify SCF. For example, one of ordinaryskill in the art can design and produce RNA aptamers or other nucleicacids that specifically recognize and bind to SCF, for instance by usingSELEX or other in vitro evolution methods known in the art. Furthermore,SCF activity can be inhibited by specifically degrading SCF or inducingan altered conformation of SCF such that it is less effective ininteracting with c-Kit. In some embodiments, the SCF inhibitor is a“designed ankyrin repeat protein” (DARPin) (see, e.g., Stumpp M T &Amstutz P, “DARPins: a true alternative to antibodies”, Curr Opin DrugDiscov Devel 2007, 10(2): 153-59, incorporated herein in its entiretyfor all purposes). In some embodiments, SCF is inhibited by a smallmolecule, e.g., a small molecule that binds to SCF and blocks itsfunction (e.g., inhibits its binding and/or other interaction (e.g., anactivating interaction) with the c-Kit receptor).

It is contemplated that altering SCF activity can be effected byinhibiting the expression of SCF, for instance, by inhibiting thetranscription of SCF, by inhibiting the translation of SCF, byinhibiting the processing of the SCF mRNA, by inhibiting the processingof the SCF polypeptide, by inhibiting the folding of the SCFpolypeptide, by inhibiting trafficking of SCF within a cell, or byinhibiting the insertion of SCF into the plasma membrane. SCF activitycan be altered by changes in chromatin structure or other means ofepigenetic regulation of SCF (e.g., changes in DNA methylation). Also,SCF activity may be altered by specifically sequestering SCF in avesicle or other cellular compartment that hinders its action uponc-Kit.

4. Therapies Using Inhibitors of SCF

Inhibiting SCF finds use in therapies to treat disease. Accordingly,provided herein are therapies comprising inhibiting SCF to benefitindividuals suffering from disease. In particular, as shown herein,disease states involving fibrosis and tissue remodeling demonstrateaberrant SCF activity. For example, fibroblasts isolated from diseasedindividuals with fibrotic or tissue remodeling phenotypes directlyrespond to SCF, which results in the generation of a more severephenotype that includes increased collagen production. As such, as shownherein, inhibiting SCF can significantly affect the generation of severedisease consequences including inflammation and remodeling of targettissue. Also contemplated are therapies targeting SCF during thegeneration of fibrosis associated with acute and chronic disorders thathave either a dynamic disease course or a more predictable diseasecourse. Indications that can benefit from therapy inhibiting SCFinclude, but are not limited to, idiopathic pulmonary fibrosis, chronicobstructive pulmonary disease, acute respiratory distress syndrome,cystic fibrosis, peribronchial fibrosis, hypersensitivity pneumonitis,asthma, sclerodoma, inflammation, liver cirrhosis, renal fibrosis,parenchymal fibrosis, endomyocardial fibrosis, mediatinal fibrosis,nodular subepidermal fibrosis, fibrous histiocytoma, fibrothorax,hepatic fibrosis, fibromyalgia, gingival fibrosis, and radiation-inducedfibrosis.

Importantly, therapies targeting SCF reduce or eliminate toxic effectsassociated with other similar therapies, for example those targetingc-Kit. These undesirable toxic effects are associated with targeting anintracellular, rather than extracellular, target, and the morewidespread and general changes in cell signaling that result. While thetherapies are not limited in their route of administration, embodimentsof the technology provided herein deliver the SCF inhibitor via theairway by intranasal administration. Such administration allows directdelivery of the therapeutic agent to target tissues in pulmonarydiseases involving fibrosis and tissue remodeling, rather than relyingon systemic delivery via an orally administered composition.

In certain embodiments, a physiologically appropriate solutioncontaining an effective concentration of an antibody specific for SCFcan be administered topically, intraocularly, parenterally, orally,intranasally, intravenously, intramuscularly, subcutaneously, or by anyother effective means. In particular, the antibody may delivered into anairway of a subject by intranasal administration. Alternatively, atissue can receive a physiologically appropriate composition (e.g., asolution such as a saline or phosphate buffer, a suspension, or anemulsion, which is sterile) containing an effective concentration of anantibody specific for SCF via direct injection with a needle or via acatheter or other delivery tube. Any effective imaging device such asX-ray, sonogram, or fiber-optic visualization system may be used tolocate the target tissue and guide the administration. In anotheralternative, a physiologically appropriate solution containing aneffective concentration of an antibody specific for SCF can beadministered systemically into the blood circulation to treat tissuethat cannot be directly reached or anatomically isolated. Suchmanipulations have in common the goal of placing an effectiveconcentration of an antibody specific for SCF in sufficient contact withthe target tissue to permit the antibody specific for SCF to contact thetissue.

With respect to administration of a SCF inhibitor (e.g., an antibodyspecific for SCF) to a subject, it is contemplated that the SCFinhibitor be administered in a pharmaceutically effective amount. One ofordinary skill recognizes that a pharmaceutically effective amountvaries depending on the therapeutic agent used, the subject's age,condition, and sex, and on the extent of the disease in the subject.Generally, the dosage should not be so large as to cause adverse sideeffects, such as hyperviscosity syndromes, pulmonary edema, congestiveheart failure, and the like. The dosage can also be adjusted by theindividual physician or veterinarian to achieve the desired therapeuticgoal.

As used herein, the actual amount encompassed by the term“pharmaceutically effective amount” will depend on the route ofadministration, the type of subject being treated, and the physicalcharacteristics of the specific subject under consideration. Thesefactors and their relationship to determining this amount are well knownto skilled practitioners in the medical, veterinary, and other relatedarts. This amount and the method of administration can be tailored toachieve optimal efficacy but will depend on such factors as weight,diet, concurrent medication, and other factors that those skilled in theart will recognize.

In some embodiments, a SCF inhibitor (e.g., an antibody specific forSCF) according to the technology provided herein is administered in apharmaceutically effective amount. In some embodiments, a SCF inhibitor(e.g., an antibody specific for SCF) is administered in atherapeutically effective dose. The dosage amount and frequency areselected to create an effective level of the SCF inhibitor withoutsubstantially harmful effects. When administered, the dosage of a SCFinhibitor (e.g., an antibody specific for SCF) will generally range from0.001 to 10,000 mg/kg/day or dose (e.g., 0.01 to 1000 mg/kg/day or dose;0.1 to 100 mg/kg/day or dose).

Pharmaceutical compositions preferably comprise one or more compounds ofthe present invention associated with one or more pharmaceuticallyacceptable carriers, diluents, or excipients. Pharmaceuticallyacceptable carriers are known in the art such as those described in, forexample, Remingtons Pharmaceutical Sciences, Mack Publishing Co. (A. R.Gennaro ed., 1985).

In some embodiments, a single dose of a SCF inhibitor (e.g., an antibodyspecific for SCF) according to the technology provided herein isadministered to a subject. In other embodiments, multiple doses areadministered over two or more time points, separated by hours, days,weeks, etc. In some embodiments, compounds are administered over a longperiod of time (e.g., chronically), for example, for a period of monthsor years (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, or more months oryears; e.g., for the lifetime of the subject). In such embodiments,compounds may be taken on a regular scheduled basis (e.g., daily,weekly, etc.) for the duration of the extended period.

In some embodiments, a SCF inhibitor (e.g., an antibody specific forSCF) according to the technology provided herein is co-administered withanother compound or more than one other compound (e.g., 2 or 3 or moreother compounds).

5. Kits

Some embodiments provide herein kits for the treatment of a subject. Insome embodiments, the kits include an inhibitor of SCF and appropriatesolutions and buffers. Embodiments include all controls and instructionsfor use.

EXAMPLES

Materials and Methods

SCF Nucleotide Sequences and Proteins

The human gene encoding Stem Cell Factor (SCF) is also known as kitligand and has the official symbol KITLG and HGNC number HGNC:6343. SCFis also known as SF; MGF; SCF; FPH2; KL-1; Kitl; SHEP7; and kit-ligand.Two transcript variants encoding different isoforms have been found forthis gene. The SCF (kit ligand) isoform b precursor is available atGenBank accession numbers NM_000899 (mRNA transcript; SEQ ID NO: 3) andNP_000890 (protein sequence; SEQ ID NO: 4). The SCF (kit ligand) isoforma precursor is available at GenBank accession numbers NM_003994 (mRNAtranscript; SEQ ID NO: 5) and NP_003985 (protein sequence; SEQ ID NO:6). The NCBI Reference Gene Sequence has accession number NG_012098 (SEQID NO: 7). For both isoforms, the first 25 amino acids comprise thesignal peptide and the mature form begins at amino acid 26. The first 11amino acids of the mature form are EGICRNRVTNN (SEQ ID NO: 8).

Bleomycin Model

Interstitial pulmonary fibrosis was induced in specific pathogen-free(SPF) female, CBA/J mice (6-8 weeks old; The Jackson Laboratory, BarHarbor, Me.) by the i.t. injection of 0.003 U of bleomycin (Blenoxane,sterile bleomycin sulfate; Bristol-Meyers Pharmaceuticals, Evansville,Ind.; 0.15 U/Kg of mouse body weight) dissolved in 60 μl ofphosphate-buffered saline (PBS). Controls received 60 μl of PBS by thesame route. All procedures were conducted in a sterile environment andwere approved by the institutional animal care and use committee.

Whole Lung Histology

Following anesthesia-induced euthanasia, whole lungs frombleomycin-challenged mice were fully inflated with 10% formalin,dissected, and placed in fresh formalin for 24 hours. Routinehistological techniques were used to embed the entire lung in paraffin,and 5-μm sections of whole lung were stained with hematoxylin and eosin.

Production and Administration of Anti-SCF Polyclonal Antibodies

Anti-SCF antibodies were generated by immunizing rabbits withrecombinant (whole protein) SCF and generating polyclonal SCF-specificantibodies. Polyclonal antibodies were isolated from the serum using aprotein G column. The isolated IgG portion was quantified and used atthe specified concentrations suspended in saline. IgG from pre-immuneserum was isolated in a similar fashion for use as a control. Briefly,100, 150 or 200 μg of control or anti-SCF was given to mice byintranasal administration 7 days after treatment with bleomycin. Thistreatment was repeated on a daily basis until 12 days after bleomycinadministration. Thus, the treatment protocol is considered therapeutic.

Generation of Mouse Anti-Human Monoclonal Antibodies

After identifying an immunogenic human peptide (e.g., SEQ ID NO: 1 or8), mice were immunized with a standard protocol. The determination ofhigh titer serum antibodies indicated the appropriate immunization andfusion hybridomas were made. Culture supernatants were analyzed fromindividual clones for SCF-specific antibody and chosen based uponspecificity. Five hybridomas producing specific monoclonal antibodiesagainst the peptide were propagated and the monoclonal with the highesttiter was subsequently tested in biologically relevant cultures. In someembodiments, a peptide having the sequence EGICRNRVTNN (SEQ ID NO: 8)was used to generate an antibody (e.g., a monoclonal antibody). In someembodiments, any peptide fragment (e.g., an antigenic fragment) of theSCF protein sequence (e.g., as provided by SEQ ID NO: 4 and/or SEQ IDNO: 6) is used to generate antibodies. In some embodiments, mutant orvariant forms (e.g., comprising one or more amino acid substitutionswith respect to the sequences provided by SEQ ID NO: 4 and SEQ ID NO: 6)of SCF are used to provide a peptide for generating antibodies. It is tobe understood that these embodiments comprise additions, deletions,substitutions, post-translational modifications (e.g., glycosylation,cyclization, N- and C-terminal modification, etc.) and other variationsof proteins and peptides that are known in the art of molecular biologyas applied to provide a peptide for antibody generation.

Testing Mouse Anti-Human Monoclonal Antibodies

To demonstrate that monoclonal antibodies inhibit SCF, mast cell linesthat are sensitive to SCF were tested. The HMC-1 cell line, amastocytoma cell line that expresses c-Kit and responds to SCF was firstused. In brief, HMC-1 cells were cultured in specific growth media andplated in 24-well tissue culture plates at a concentration of 1×10⁶cells/ml. Recombinant human SCF (1-100 ng/ml) was mixed with monoclonalanti-SCF antibody (12 μg/ml) and incubated at 37° C. for 30 minutes.After incubation, the antibody/SCF or SCF alone was added to the HMC-1cells. After 1 hour or 24 hours, the cultured HMC-1 cells were harvestedand mRNA and protein levels were measured as an indication of SCFinhibition by the monoclonal antibodies.

Analysis of mRNA Expression by Quantitative PCR

Cells or tissue to be tested were dispersed in 1 ml of Trizol reagent(Invitrogen). RNA was isolated as described (Invitrogen), and 5 μg ofmRNA was reverse-transcribed to assess gene expression. Detection ofcytokine mRNA was determined using previously available primer/probesets (PE Biosystems, Foster City, Calif.) and analyzed using an ABIPrism 7500 Sequence Detection System (Applied Biosystems, Foster City,Calif.). GAPDH mRNA was measured as a control for normalizing mRNAexpression. Changes in gene expression were calculated relative to geneexpression in unchallenged mice.

Determination of Cytokine Production

Protein levels of cytokines were quantified using a Bio-Plex bead-basedcytokine assay purchased from Bio-Rad Laboratories (Hercules, Calif.).Using standard protocols, the level of cytokines can be quickly andconsistently assessed with this methodology.

Statistical Analysis

Data were analyzed using Prism GraphPad software. Unless otherwisespecified, data shown are representative of two or more experiments.Statistical significance in all experiments was determined by one-wayANOVA, followed by a Newman-Keuls post test. Significant differenceswere regarded as p<0.05.

Isolation and Propagation of Pulmonary Fibroblasts from PatientPopulations

The Institutional Review Board at the University of Michigan MedicalSchool approved this study. All patients underwent clinical evaluation,including chest radiography, lung function measurements, andthin-section computed tomography before fiber optic bronchoscopy. Inthese patients, interstitial pneumonia was determined from a compilationof symptoms, physiological symptoms, and radiographical findings.Surgical lung biopsies were obtained via the Clinical Core at theUniversity of Michigan Medical School from patients suspected of havinginterstitial pneumonia between May 2000 and May 2002. Histologicallynormal lung was obtained from resected specimens in patients undergoingthoracic resection. Each biopsy was processed separately using steriletechnique in a laminar flow hood and processed for culturing primaryfibroblast lines. Two pathologists who were unaware of any otherclinical findings independently reviewed each biopsy and histologicalclassification was based on previously published criteria for idiopathicinterstitial pneumonia.

Interstitial pneumonia and normal biopsies were finely minced and thedispersed tissue pieces were placed into 150-cm² cell culture flasks(Corning Inc., Corning, N.Y.) containing Dulbecco's modified Eagle'smedium (DMEM, BioWhittaker, Walkersville, Md.) supplemented with 15%fetal bovine serum (DMEM-15, BioWhittaker), 1 mmol/L glutamine(BioWhittaker), 100 U/ml penicillin (BioWhittaker), 100 μg/mlstreptomycin (BioWhittaker), and 0.25 μg amphotericin B (Fungizone;BioWhittaker). All primary lung cell lines were maintained in DMEM-15 at37° C. in a 5% CO₂ incubator and were serially passaged a total of fivetimes to yield pure populations of lung fibroblasts. All primaryfibroblast cell lines were used at passages 6 to 10 in the experimentsoutlined below and all of the experiments were performed undercomparable conditions.

1. Anti-SCF Antibody Reduces Fibrosis and Inflammation

Experiments conducted while developing embodiments of the technologydemonstrated that anti-SCF antibody reduced fibrosis and inflammation.Pulmonary fibrosis was induced in mice as described. On day 7 followingbleomycin injury, mice were subjected to treatment with anti-SCFantibodies delivered into the airway by intranasal administration.Treatment continued until day 12 following bleomycin exposure. Lungswere harvested on day 16 and examined by microscopy and a series ofmicrographs were taken. Lung histology demonstrated that anti-SCFantibodies reduced overall inflammation. In addition, Masson's trichromestaining, which designates collagen deposition, was reduced.

2. Anti-SCF Antibody Reduces Levels of SCF, Hydroxyproline, IL-25, andIL-13

Levels of hydroxyproline and particular cytokines were monitored whiledeveloping embodiments of the technology. Lung tissue sections from theabove experiment were examined for the presence of hydroxyproline, acollagen precursor. The data demonstrated that the anti-SCF antibodyreduced the production of hydroxyproline and plasma levels of SCF in adose-dependent manner (FIGS. 1A and D). Also, IL-25 and IL-13expression, measured as a function of mRNA levels, were reduced, as wasexpression of IL-25 receptor (FIGS. 1B, C, and E).

In particular, the experiments tested the effect of anti-SCF antibodytreatment in the BLM model (FIG. 1). Mice were treated with saline (FIG.1, “SAL”) or BLM (FIG. 1, “BLM”) on day 0. On days 8 and 12, differentgroups were also treated intratracheally with non-immune (FIG. 1, “IgG”)or anti-SCF antibodies (FIG. 1, “aSCF”) at the indicated doses. H&Estained lung tissue sections from each treatment group were acquired andexamined. Fibrosis was quantified biochemically as lung hydroxyprolinecontent (FIG. 1A). Lungs were then analyzed for IL-13 mRNAs by real timePCR (FIG. 1C). Plasma and lung tissue collected from SAL- or BLM-treatedmice were then analyzed for soluble SCF by ELISA (FIG. 1D) or IL-25 mRNAby real time PCR (FIG. 1B). Values represent the means+/−the standarderror with an n=7. A single asterisk (*) indicates statisticalsignificance (P<0.05) when compared to the saline control group, whiledouble asterisks (**) indicate significance with respect to the BLM+IgGcontrol group.

3. IL-4 Stimulates c-Kit Expression in Human Fibroblasts

Experiments conducted while developing embodiments of the technologydemonstrated that IL-4 stimulated c-kit expression in human fibroblasts.In addition to the mouse model of pulmonary inflammation, SCF receptoris expressed in fibroblast populations from patients diagnosed withhypersensitivity pneumonitis and who thus have a pro-fibroticenvironment. Pulmonary fibroblasts were grown from normal areas of lungsfrom patients (normal) and those diagnosed with hypersensitivitypneumonitis. Expression of c-kit was measured after stimulation withIL-4 at 1 or 10 ng/ml. Individual cell lines (133, 131, 173, 177A, 177B)were assessed using real-time PCR. Compared to lung fibroblasts grownfrom patients with non-fibrotic disease, fibroblasts from thehypersensitivity pneumonitis patients displayed significant upregulationof c-kit when stimulated with IL-4, a fibrosis-associated cytokine. Thedata demonstrated that SCF activated fibroblasts from inflammatorylesions, but not those from normal tissue, and promoted the expressionof fibrosis-associated genes including collagen (FIG. 2).

4. A Mouse Anti-Human Monoclonal Antibody Blocks SCF-Induced HMC MastCell Activation.

Experiments conducted while developing embodiments of the technologydemonstrated that the monoclonal antibody specific for SCF inhibited theactivation of HMC-1 cells for MCP-1 production. The activation of mastcells is a classic SCF-induced response that can be used to monitorantibody neutralization of SCF-mediated cytokine responses. Previousstudies have demonstrated that monocyte chemotactic protein (MCP)-1 isstrongly upregulated by SCF in mast cells. A monoclonal antibody wasproduced against SEQ ID NO: 1 (FIG. 3). The efficacy of this antibodywas tested using a human mast cell line, HMC-1, stimulated with 100ng/ml of SCF. The monoclonal antibody (6 μg/ml) was preincubated withthe recombinant SCF for 5 minutes prior to placing the SCF or the SCFplus anti-SCF onto the cultured HMC-1 cells (1×10⁶ cells/ml). The cellswere subsequently incubated for 12 hours, after which the cell-freesupernatant was collected and MCP-1 was analyzed by Bio-Plex. The dataillustrate that the monoclonal antibody specific for SCF inhibited theactivation of HMC-1 cells for MCP-1 production (FIG. 4).

5. SCF-Deficient Mice Subjected to BLM-Induced Injury have ReducedFibrosis.

During the development of embodiments of the technology provided herein,the effects of SCF deficiency in Kitl^(S1)/Kitl^(S1-d) mutant mice wereexamined (FIG. 5). These mice have a complete deletion of the SCF genein one allele (S1) and a deletion of the membrane-bound ligand in theother (S1^(d)), which significantly decreases the expression of solubleSCF. When these mice and their wild type controls (WT) were subjected toBLM-induced lung injury, there was a significantly reduced fibrosis inthe mutant mice compared to wild type mice, both morphologically (Massontrichrome stain) and biochemically by hydroxyproline analysis (FIG. 5).

Wild-type and SCF deficient mice were treated with saline (“SAL”) or BLM(“BLM”) on day 0 and lungs were harvested 21 days later. Fibrosis wasquantified biochemically as lung hydroxyproline content. Valuesrepresent the mean+/−standard deviation with an n=3. A single asterisk(*) indicates statistical significance (P<0.05) when compared to the WTsaline-treated control mean, while double asterisks (**) indicatesignificance when compared to the WT BLM-treated group.

Similar suppression of cytokine expression and telomerase induction wasalso noted in S1/S1d mice. These data taken together indicated anessential role for the SCF/c-Kit signaling induced pulmonary fibrosis.

All publications and patents mentioned in the above specification areherein incorporated by reference in their entirety for all purposes.Various modifications and variations of the described compositions,methods, and uses of the technology will be apparent to those skilled inthe art without departing from the scope and spirit of the technology asdescribed. Although the technology has been described in connection withspecific exemplary embodiments, it should be understood that theinvention as claimed should not be unduly limited to such specificembodiments. Indeed, various modifications of the described modes forcarrying out the invention that are obvious to those skilled inpharmacology, biochemistry, medical science, or related fields areintended to be within the scope of the following claims.

We claim:
 1. A method of treating a subject, the method comprisingadministering to the subject an anti-stem cell factor antibody thatspecifically binds to stem cell factor isoform b relative to stem cellfactor isoform a or an antigen-binding antibody fragment thatspecifically binds to stem cell factor isoform b relative to stem cellfactor isoform a.
 2. The method of claim 1 wherein the antibody or theantigen-binding antibody fragment specifically binds to a proteincomprising an amino acid sequence provided by SEQ ID NO: 4 or anantibody-binding fragment thereof.
 3. The method of claim 1 wherein theantibody is a monoclonal antibody or the antigen-binding antibodyfragment is a fragment of a monoclonal antibody.
 4. The method of claim1 wherein the antibody is a polyclonal antibody.
 5. The method of claim1 wherein the antibody is a humanized antibody or chimeric antibody orthe antigen-binding antibody fragment is a fragment of a humanized or achimeric antibody.
 6. The method of claim 1 wherein the antibody orantigen-binding antibody fragment is a Fab, a Fab′, a F(ab′), a Fvfragment, a scFv fragment, or a linear antibody.
 7. The method of claim1 comprising administering the anti-stem cell factor antibody orantigen-binding antibody fragment in a physiologically appropriatesolution to the subject.
 8. The method of claim 1 comprisingadministering the anti-stem cell factor antibody or antigen-bindingantibody fragment into an airway of a subject.
 9. The method of claim 1wherein the subject has a fibrosis or a tissue remodeling disease. 10.The method of claim 1 wherein the subject has idiopathic pulmonaryfibrosis, chronic obstructive pulmonary disease, acute respiratorydistress syndrome, cystic fibrosis, peribronchial fibrosis,hypersensitivity pneumonitis, asthma, sclerodoma, inflammation, livercirrhosis, renal fibrosis, parenchymal fibrosis, endomyocardialfibrosis, mediastinal fibrosis, nodular subepidermal fibrosis, fibroushistiocytoma, fibrothorax, hepatic fibrosis, fibromyalgia, gingivalfibrosis, or radiation-induced fibrosis.
 11. The method of claim 1wherein the subject is in need of inhibition of SCF.
 12. The method ofclaim 1 comprising administering the anti-stem cell factor antibody orantigen-binding antibody fragment by a topical, intraocular, parenteral,oral, buccal, intranasal, intravenous, intramuscular, or subcutaneousroute.
 13. The method of claim 1 comprising administering apharmaceutically effective amount of the anti-stem cell factor antibodyor antigen-binding antibody fragment to the subject.
 14. The method ofclaim 1 comprising administering a plurality of doses of the anti-stemcell factor antibody or antigen-binding antibody fragment to thesubject.
 15. The method of claim 1 comprising administering theanti-stem cell factor antibody or antigen-binding antibody fragment in aphysiologically appropriate solution comprising a pharmaceuticallyacceptable carrier, diluent, or excipient.